Gilead Stock Reverses; Why Its Buy-Side Miss Isn't The End For Its New HIV Shot

EARNINGS PREVIEW: Palantir, Robinhood Among Leaders Set To ReportGilead stock reversed its losses early Friday as analysts noted encouraging indicators for its newly approved HIV prevention shot.Yeztugo is a twice-annual injection that aims to prevent HIV infection from taking hold in at-risk people. During the third quarter, it generated $39 million in sales, RBC Capital Markets analyst Brian Abrahams said in a report. He acknowledged that while sales beat sell-side expectations for $35 million, the buy-si ...